Live
FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonistsBioWorldIteos Belgium discloses new PTPN1/2 inhibitorsBioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIVBioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patentLabiotechNew names, new narratives: Why biotechs decide to rebrandPharmaVoiceThe biotech market is rebounding. So where are the executive jobs?FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A options
Waters Mar 16, 2026

Winners And Losers Of Q4: Waters Corporation (NYSE:WAT) Vs The Rest Of The Research Tools & Consumables Stocks - StockStory

Winners And Losers Of Q4: Waters Corporation (NYSE:WAT) Vs The Rest Of The Research Tools & Consumables Stocks - StockStory

Body unavailable. Use the original source.